The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than $2.5 million per quarter...
Cannabis stocks, as measured by the Global Cannabis Stock Index, fell slightly in April, declining 0.5% to 107.33, after bouncing twice near 95 early in the month: The index, which went through...
Last week, GW Pharma (NASDAQ: GWPH) scored a milestone victory, as the thirteen-member panel at the Peripheral and Central Nervous System Drugs Advisory Committee, which met on April 19th to consider...
This is a copy of the April 22nd, Sunday edition of our weekly Newsletter which we have been publishing since October, 2015. Friends, We think that we are on...
Almost five years ago, a few months after GW Pharma (NASDAQ: GWPH) conducted its NASDAQ IPO, CNN shared a documentary narrated by its Chief Medical Correspondent, Dr. Sanjay Gupta,...
The potentially first botanically-derived FDA-approved cannabis-based product moved closer to approval today, as an Advisory Committee discussed the safety and efficacy of Epidolex, intended to treat seizures in children...
GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP42006 -Study did not meet its primary endpoint- -Company remains committed to continued development of GWP42006...
The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than $2.5 million per quarter....
After the close, GW Pharma (NASDAQ: GWPH) issued two press releases and hosted a conference call to review its FY18-Q1 ending 12/31/17. The company reported that the European Medicines...
GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Publication of Landmark Epidiolex(R) (cannabidiol) Study in The Lancet First well-controlled clinical study of cannabidiol in Lennox-Gastaut syndrome, a rare,...
GW Pharmaceuticals Announces Acceptance of NDA Filing for Epidiolex(R) (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome LONDON and CARLSBAD, Calif., Dec. 28, 2017 (GLOBE NEWSWIRE) —...
GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs Raising Gross Proceeds of $317.4 Million and Full Exercise of Underwriter’s Option to Purchase Additional ADSs LONDON, UK,...
GW Pharmaceuticals Announces Proposed Public Offering of ADSs LONDON, Dec. 05, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (GWPRF) (Nasdaq:GWPH) (“GW” or the “Company”), a biopharmaceutical company focused on...
GW Pharmaceuticals plc Reports Fiscal Fourth Quarter 2017 and Year-End Financial Results and Operational Progress Epidiolex® (cannabidiol) NDA Submitted to FDA Conference call today at 7:30 a.m. EST LONDON...
GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Completes Rolling New Drug Application Submission to U.S. Food and Drug Administration for Epidiolex(R) (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome...
Horizons Medical Marijuana Life Sciences ETF (TSX: HMMJ) (OTC: HMLSF), the world’s first and still only cannabis ETF, has adjusted its portfolio this month as its benchmark, the North...
In contrast to a period when promotion and fluff have grabbed the attention of novice stock investors interested in the legal cannabis theme since early 2013, we are now seeing companies...
Horizons Marijuana Life Sciences Index ETF (TSX: HMMJ) (OTC: HMLSF) has been hit hard over the past two weeks, declining 8.4% since July 26th despite what has been a stable market...
GW Pharma (NASDAQ: GWPH) issued a press release after the close of trading on Monday to report its FY17-Q3 financials and provide an operational update. The most significant news...
As the U.S. cannabis industry has evolved over the past few years, so has the market for publicly-traded cannabis stocks. In 2014, very few publicly-traded companies were reporting substantial...
Let’s face it, when it comes to cannabis stocks, Canada continues to crush the United States, where federal illegality makes it more difficult to operate and to raise capital....
GW Pharmaceuticals Announces Epidiolex(R) Receives Orphan Drug Designation from the European Medicines Agency for the Treatment of Lennox-Gastaut Syndrome LONDON, March 29, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc...
The Roland George Investments Program (RGIP), a student-managed portfolio worth $3.5 million at Stetson University in Florida, is investing in the cannabis industry. The program, headed by Dr. K.C....
Earlier this week, we highlighted a story published on Leafly regarding lobbying efforts by GW Pharma (NASDAQ: GWPH). Leafly’s Bruce Barcott discovered that GW Pharma and its U.S. subsidiary,...
Note: We published a follow up to this article Leafly’s Bruce Barcott has uncovered some actions taken by GW Pharma (NASDAQ: GWPH) that appear to be part of an...
